Eisai Inc.
Clinical trials sponsored by Eisai Inc., explained in plain language.
-
Promising Alzheimer's drug slows memory loss in major trial
Disease control CompletedThis study tested a drug called lecanemab (BAN2401) in 856 people with early Alzheimer's disease (mild memory problems or mild dementia). The goal was to see if the drug could slow down worsening of memory and thinking skills compared to a placebo. Participants received different…
Phase: PHASE2 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated May 17, 2026 08:00 UTC
-
Promising combo slows advanced uterine cancer in large trial
Disease control CompletedThis phase 3 trial tested whether combining two drugs, lenvatinib and pembrolizumab, works better than standard chemotherapy for people with advanced endometrial cancer that has returned or spread. Over 800 participants were randomly assigned to receive either the drug combo or a…
Phase: PHASE3 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New combo shows promise for tough cancers
Disease control CompletedThis study tested a new drug called E7386 combined with the immunotherapy pembrolizumab (and sometimes lenvatinib) in 89 people with advanced melanoma, colorectal cancer, or liver cancer that had stopped responding to prior treatments. The goal was to check safety and find the ri…
Phase: PHASE1, PHASE2 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated May 13, 2026 16:03 UTC